NLG919 CAS NO.1402836-58-1

长沙雁飞生物科技有限公司位于国家生物产业基地——长沙市生物医药园,是一家致力于天然药物活性成分现代化、产业化研究,集开发、生产、销售高标准高质量高科技产品为一体的高新科技企业。 公司下设研发、生产、销售等多个部门。公司研发中心拥有多台高效液相色谱、紫外分析仪等先进检测实验仪器,配备人员均为本科及以上学历,对工艺研究、质量保证、质量检测三项职能进行了明细分工,以此对生产过程进行有效全面的质量控制,对最终产品进行全面检测,以确保产品品质。公司在高速发展的同时,坚持自主研发与合作研发相结合,与湖南、广东、上海等地多家高校和科研机构长期合作,为高纯度活性单体和标准化提取物工业化生产提供强有力的保障。

NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.
IC50 value: 7 nM/75 nM(Ki/EC50)
Target: indoleamine-(2,3)-dioxygenase inhibitor
NLG919 potently blocks IDO-induced T-cell suppression and restored robust T-cell responses with ED50 of 80 nM. Similarly, using IDO-expressing mouse DCs from tumor-draining lymph nodes, NLG919 abrogated IDO-induced suppression of antigen-specific T cells (OT-I) in vitro, with ED50 of 120 nM. In mice, a single oral administration of NLG919 reduces the concentration of plasma and tissue Kyn by ~ 50%. In mice bearing B16F10 tumors, NLG919 markedly enhances the antitumor responses of naive, resting pmel-1 cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA.